Key Highlights

  • First Tracks Biotherapeutics (NASDAQ:TRAX) traded at USD 36.78 to USD 38.61 premarket versus a USD 31.85 close, a rise of about 15% to 21%, simple arithmetic on published quotes.
  • Phase 1b celiac data showed a villus-to-crypt ratio change of -0.17 versus -0.66 on placebo, with a p-value of 0.009, a verified result from the company release on October 12, 2026.
  • The study is small and early, so a statistically significant result does not establish that First Tracks Biotherapeutics (NASDAQ:TRAX) has an effective, safe celiac treatment.
  • Premarket quotes can differ sharply from the regular session, and the move should be rechecked after the 9:30 a.m. ET open. Investors should confirm the move once regular trading begins.

The Data and the Move

First Tracks Biotherapeutics (NASDAQ:TRAX) reported positive Phase 1b data in celiac disease on October 12, 2026, and shares traded between USD 36.78 and USD 38.61 premarket against a USD 31.85 close. That is a gain of about 15.5% to 21.2%, simple arithmetic on published prices. Celiac disease is an immune reaction to gluten that flattens the finger-like villi lining the small intestine. The villus-to-crypt ratio compares villus height with the depth of the glands beneath, and a smaller drop signals less damage. The ratio changed by -0.17 on treatment versus -0.66 on placebo, with a p-value of 0.009. The full presentation was not reviewed. Study size was not captured.

What the Result Means

A p-value of 0.009 suggests the difference is unlikely to be due to chance in this study, but p-values do not measure clinical benefit. The trial design, the number of patients, the dose and the gluten challenge method were not captured in published information. Phase 1b studies are small and mainly test safety and early biological effect, so the signal needs confirmation in larger Phase 2 trials. Celiac patients currently manage the disease only by avoiding gluten, so a treatment would address a real need, but the path from histology to symptoms and daily life is longer than one early dataset. Larger studies also measure symptoms, blood markers and the effect of real-world gluten exposure, which matter to patients.

Risks and What to Watch

Clinical-stage biotechs are volatile, and early premarket jumps can fade. First Tracks Biotherapeutics (NASDAQ:TRAX) listed on Nasdaq in 2026 after a spin-off, according to company materials, so its trading history is short. Investors can watch for the full data presentation, the Phase 2 plan and any financing, since companies often raise capital after a share price jump, which dilutes existing holders. Safety findings, patient dropouts and regulatory feedback are further risks. This article does not suggest that the shares will keep rising, and quotes should be rechecked after the open. A second risk is that a placebo group in a small study can behave unexpectedly.

Where Things Stand

First Tracks Biotherapeutics (NASDAQ:TRAX) jumped because early celiac data showed a smaller loss of intestinal structure on treatment than on placebo, with a p-value of 0.009. The study is small, the quotes are premarket and the result needs confirmation. Details of the study and any financing plans will show how durable the move proves for First Tracks Biotherapeutics (NASDAQ:TRAX). The honest reading is cautious: the result is statistically significant in a small dataset, and the premarket reaction prices in a lot of hope before larger studies have been run.